SLIT Risks: A Balanced Look at Sublingual Immunotherapy

The most common risk of sublingual immunotherapy is also the least serious: local reactions in and around the mouth. These include itching under the tongue, throat irritation, ear itching, and minor lip or tongue swelling, and they affect roughly 40.8 percent of patients according to a 2024 meta-analysis. They typically begin within minutes of dosing, settle quickly, and ease over the early weeks as the mouth adapts. A smaller number of people experience mild gastrointestinal effects such as nausea. These common risks are generally mild and self-limiting rather than dangerous, which is why most SLIT dosing happens at home after a supervised first dose. The rarer and more serious risks, systemic reactions and anaphylaxis, are far less frequent. Understanding that the common risks are minor while the serious risks are rare is the most accurate way to weigh whether SLIT is right for you, ideally in discussion with your provider.

The risk of a serious reaction with sublingual immunotherapy is low. Systemic reactions, those involving the body beyond the mouth such as widespread hives or wheezing, occur in fewer than 0.1 percent of patients in our program and are usually mild. The most serious reaction, anaphylaxis, is exceptionally rare, estimated near 1 per 100 million doses, and no SLIT fatality has been reported worldwide across decades of use. So while serious reactions are possible, they are uncommon, and life-threatening ones are exceptionally so. The practical safeguards reflect this balance: providers often supervise the first dose and may prescribe an epinephrine auto-injector, and candidates with uncontrolled or severe asthma are excluded because asthma raises the stakes of a systemic reaction. Knowing the red flags, such as difficulty breathing or throat swelling, and having an emergency plan is the sensible way to manage the small chance of a serious event.

Eosinophilic esophagitis, often abbreviated EoE, is a recognized but rare risk associated with sublingual immunotherapy, and it is important enough that it is considered a contraindication. EoE is an inflammatory condition of the esophagus driven by an accumulation of eosinophils, and it typically presents as progressively worsening difficulty swallowing or a sensation of food sticking in the chest. The association appears to relate to the swallowed portion of the allergen extract. Because it is a contraindication, people with known EoE generally should not start sublingual immunotherapy, and anyone who develops persistent swallowing difficulty during treatment should stop and contact their provider for evaluation, which may involve a referral to gastroenterology. While EoE is uncommon, it is worth knowing about before starting any sublingual immunotherapy program, since recognizing the symptoms early allows for prompt assessment and, if needed, discontinuation of treatment.

Asthma is directly relevant to SLIT risk, which is why providers screen for it before treatment. Specifically, uncontrolled or severe asthma is a contraindication, because poorly controlled airways increase the potential severity of a systemic reaction. The important distinction is control: well-controlled asthma is generally not a barrier to sublingual immunotherapy, while uncontrolled asthma is. For this reason, achieving good asthma control is a prerequisite before starting, and your provider may assess your breathing as part of the evaluation. For someone with stable, well-managed asthma, the overall risk profile of SLIT remains favorable, in line with its mostly mild and local side effects. The takeaway is that asthma raises SLIT risk only when it is not well controlled, and addressing control first is the safe approach. Always be candid with your provider about any breathing problems so they can decide whether and when SLIT is appropriate for you.